According to our recent payer coverage analysis for chemotherapy-induced nausea and vomiting (CINV) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for CINV treatments shows that under the pharmacy benefit, about 25% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: New entrants to this market have benefited from rapid uptake, driven both by clinical advantages and by favorable reimbursement dynamics. Merck & Co., Inc.’s Emend (aprepitant) and Aloxi (palonosetron hydrochloride) have the most favorable coverage compared with other brand name antiemetics.